22.5 USD
+2.16 (+10.62%)
22.4982 USD
0 (-0.01%)
Taking everything into account, ASTH scores 4 out of 10 in our fundamental rating. ASTH was compared to 101 industry peers in the Health Care Providers & Services industry. While ASTH is still in line with the averages on profitability rating, there are concerns on its financial health. ASTH is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
ASTH had positive earnings in the past year.
In the past year ASTH had a positive cash flow from operations.
ASTH had positive earnings in each of the past 5 years.
ASTH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ASTH has a Return On Assets of 0.43%. This is comparable to the rest of the industry: ASTH outperforms 51.49% of its industry peers.
ASTH has a Return On Equity of 1.23%. This is comparable to the rest of the industry: ASTH outperforms 57.43% of its industry peers.
ASTH has a Return On Invested Capital of 2.95%. This is comparable to the rest of the industry: ASTH outperforms 47.52% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ASTH is below the industry average of 9.38%.
The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROIC | 2.95% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
1.3 Margins
ASTH has a Profit Margin (0.33%) which is in line with its industry peers.
ASTH's Profit Margin has declined in the last couple of years.
With a Operating Margin value of 2.59%, ASTH perfoms like the industry average, outperforming 51.49% of the companies in the same industry.
ASTH's Operating Margin has declined in the last couple of years.
ASTH's Gross Margin of 10.25% is on the low side compared to the rest of the industry. ASTH is outperformed by 73.27% of its industry peers.
In the last couple of years the Gross Margin of ASTH has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% |
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ASTH has more shares outstanding
The debt/assets ratio for ASTH is higher compared to a year ago.
2.2 Solvency
ASTH has an Altman-Z score of 2.19. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ASTH (2.19) is comparable to the rest of the industry.
ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
With a Debt to FCF ratio value of 10.83, ASTH perfoms like the industry average, outperforming 42.57% of the companies in the same industry.
A Debt/Equity ratio of 1.29 is on the high side and indicates that ASTH has dependencies on debt financing.
ASTH has a Debt to Equity ratio of 1.29. This is in the lower half of the industry: ASTH underperforms 64.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Altman-Z | 2.19 |
ROIC/WACC0.33
WACC8.83%
2.3 Liquidity
ASTH has a Current Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ASTH (1.40) is comparable to the rest of the industry.
ASTH has a Quick Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.40, ASTH perfoms like the industry average, outperforming 56.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 |
3. Growth
3.1 Past
ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.38%.
ASTH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.19% yearly.
The Revenue has grown by 68.17% in the past year. This is a very strong growth!
ASTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.01% yearly.
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
3.2 Future
Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 31.87% on average per year.
Based on estimates for the next years, ASTH will show a very strong growth in Revenue. The Revenue will grow by 20.51% on average per year.
EPS Next Y37.27%
EPS Next 2Y52.9%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 118.42, ASTH can be considered very expensive at the moment.
ASTH's Price/Earnings is on the same level as the industry average.
ASTH is valuated expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 10.81, which indicates a very decent valuation of ASTH.
ASTH's Price/Forward Earnings ratio is rather cheap when compared to the industry. ASTH is cheaper than 86.14% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, ASTH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.42 | ||
| Fwd PE | 10.81 |
4.2 Price Multiples
ASTH's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 79.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.59 | ||
| EV/EBITDA | 15.17 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ASTH's earnings are expected to grow with 45.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.18
PEG (5Y)6.17
EPS Next 2Y52.9%
EPS Next 3Y45.45%
5. Dividend
5.1 Amount
No dividends for ASTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.5
+2.16 (+10.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.14%
Inst Owner ChangeN/A
Ins Owners9.76%
Ins Owner Change1.1%
Market Cap1.12B
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts85
Price Target43.22 (92.09%)
Short Float %5.17%
Short Ratio4.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.83%
PT rev (3m)-3.45%
EPS NQ rev (1m)-24.47%
EPS NQ rev (3m)-29.06%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.99%
Revenue NQ rev (1m)-3.75%
Revenue NQ rev (3m)-3.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 118.42 | ||
| Fwd PE | 10.81 | ||
| P/S | 0.39 | ||
| P/FCF | 11.59 | ||
| P/OCF | 10.55 | ||
| P/B | 1.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.17 |
EPS(TTM)0.19
EY0.84%
EPS(NY)2.08
Fwd EY9.25%
FCF(TTM)1.94
FCFY8.63%
OCF(TTM)2.13
OCFY9.48%
SpS58.01
BVpS15.53
TBVpS-7.47
PEG (NY)3.18
PEG (5Y)6.17
Graham Number8.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.43% | ||
| ROE | 1.23% | ||
| ROCE | 4.68% | ||
| ROIC | 2.95% | ||
| ROICexc | 4.15% | ||
| ROICexgc | N/A | ||
| OM | 2.59% | ||
| PM (TTM) | 0.33% | ||
| GM | 10.25% | ||
| FCFM | 3.35% |
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.29 | ||
| Debt/FCF | 10.83 | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 25.55% | ||
| Cap/Sales | 0.33% | ||
| Interest Coverage | 2.01 | ||
| Cash Conversion | 94.59% | ||
| Profit Quality | 1016.69% | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.4 | ||
| Altman-Z | 2.19 |
F-Score3
WACC8.83%
ROIC/WACC0.33
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y37.27%
EPS Next 2Y52.9%
EPS Next 3Y45.45%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year61.55%
Revenue Next 2Y43.26%
Revenue Next 3Y31.12%
Revenue Next 5Y20.51%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year116.25%
EBIT Next 3Y48.23%
EBIT Next 5Y33.37%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A
ASTRANA HEALTH INC / ASTH FAQ
Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?
ChartMill assigns a fundamental rating of 4 / 10 to ASTH.
What is the valuation status for ASTH stock?
ChartMill assigns a valuation rating of 5 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.
How profitable is ASTRANA HEALTH INC (ASTH) stock?
ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.
What is the financial health of ASTRANA HEALTH INC (ASTH) stock?
The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.
Is the dividend of ASTRANA HEALTH INC sustainable?
The dividend rating of ASTRANA HEALTH INC (ASTH) is 0 / 10 and the dividend payout ratio is 86.52%.